Sugi Predict

Sugi Predict / Compounds / SCHEMBL6043531

SCHEMBL6043531

SCHEMBL6043531

COCCCN1CCN([C]=O)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ SLC29A1 Q99808 2/20 0.35
▸ DRD2 P14416 2/20 0.34
▸ HSD11B1 P28845 1/20 0.33
▸ HRH3 Q9Y5N1 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ ABCC4 O15439 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6043792 0.94 SLC29A1 (0.36) KDM4EALDH1A1SLC29A1HSD11B1HRH3
SCHEMBL1783124 0.88 HSD11B1 (0.41) KDM4EALDH1A1SLC29A1HSD11B1MEN1
SCHEMBL11575418 0.83 — —
SCHEMBL10924619 0.83 ALDH1A1 (0.39) KDM4EALDH1A1SLC29A1DRD2HRH3
SCHEMBL6042750 0.81 CYP2D6 (0.35) KDM4EHRH3CYP2D6MAPK1SLC6A4
SCHEMBL10930283 0.79 HSD11B1 (0.42) KDM4EALDH1A1SLC29A1HSD11B1HRH3
SCHEMBL6042277 0.78 DRD2 (0.40) KDM4EALDH1A1SLC29A1DRD2HSD11B1
SCHEMBL4630069 0.78 GNAI3 (0.44) KDM4EDRD2LMNAHTR2A
SCHEMBL6945807 0.78 ALDH1A1 (0.38) KDM4EALDH1A1SLC29A1DRD2HSD11B1
SCHEMBL8880908 0.78 ALDH1A1 (0.38) KDM4EALDH1A1SLC29A1DRD2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060089355-A1 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides ELAN PHARMACEUTICALS, INC. 2006-04-27 — — US disclosed
WO-2003103652-A1 METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES ELAN PHARMACEUTICALS, INC. (US) 2003-12-18 — — WO disclosed
US-5641778-A EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-06-24 — — US disclosed
EP-0716077-A1 Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors CIBA-GEIGY AG (CH) 1996-06-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089355-A1 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides APP, BACE1, BACE2 KDM4E 1951/4885ALDH1A1 1039/4885SLC29A1 2415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.